Physician profile
Steven Gruenstein
NPI 1407855307
$2,563.35
in general payments reported to CMS, 2019-2025
38 companies · $61.81 in 2025
The $61.81 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $577 · 2021: $497 · 2023: $465 · 2024: $66.09 · 2025: $61.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.18 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $423.72 | 2019-2023 | |
| Kite Pharma, INC. | $236.32 | 2020-2021 | |
| Gilead Sciences, INC. | $221.66 | 2019-2024 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $143.09 | 2019-2023 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $135.50 | 2020-2023 | Rezlidhia, Tavalisse |
| E.R. Squibb & Sons, L.L.C. | $118.58 | 2019 | |
| Janssen Biotech, INC. | $114.16 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $106.14 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $92.38 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.41 | 2019-2023 | Ninlaro |
| Janssen Pharmaceuticals, INC | $69.62 | 2019-2020 | |
| Incyte Corporation | $61.33 | 2019-2021 | |
| Lilly USA, LLC | $58.10 | 2019-2020 | |
| Astellas Pharma US INC | $55.69 | 2021-2023 | Padcev |
| Pfizer INC. | $54.28 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $45.74 | 2021 | |
| Tersera Therapeutics LLC | $44.99 | 2023 | Xermelo, Zoladex |
| Amgen INC. | $43.86 | 2019-2020 | |
| Genentech USA, INC. | $42.42 | 2019-2021 | |
| Emd Serono, INC. | $39.61 | 2025 | |
| Seagen INC. | $39.28 | 2019-2020 | |
| Adc Therapeutics America, INC. | $29.35 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $23.28 | 2019 | |
| Puma Biotechnology, INC. | $22.72 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $22.44 | 2020 | |
| Shield Therapeutics INC | $22.20 | 2025 | |
| Sun Pharmaceutical Industries INC. | $20.62 | 2021 | |
| Myovant Sciences INC. | $20.44 | 2021 | |
| Sanofi Pasteur INC. | $20.03 | 2019 | |
| Array Biopharma INC | $19.26 | 2019 | |
| Abbvie INC. | $18.74 | 2020 | |
| Glaxosmithkline, LLC. | $18.41 | 2021 | |
| Kyowa Kirin, INC. | $18.21 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.91 | 2019 | |
| Stemline Therapeutics INC. | $17.16 | 2019 | |
| Agios Pharmaceuticals, INC. | $16.53 | 2024 | Pyrukynd |
| Advanced Accelerator Applications | $16.50 | 2020 | |
| Partner Therapeutics, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Gruenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.